Research progress on the pathological mechanism of meibomian gland dysfunction in diabetic patients
10.3980/j.issn.1672-5123.2024.7.17
- VernacularTitle:糖尿病患者睑板腺功能障碍病理机制的研究进展
- Author:
Yize HAN
1
,
2
;
Kejun LI
1
,
2
;
Qingmin MA
1
,
2
;
Fang FAN
1
,
2
;
Wenwen TANG
1
,
2
;
Jing CHENG
1
,
2
;
Linwei YAN
1
,
2
;
Yafeng WANG
1
,
2
Author Information
1. Department of Ophthalmology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China
2. Hebei Medical University, Shijiazhuang 050017, Hebei Province, China
- Publication Type:Journal Article
- Keywords:
meibomian gland dysfunction;
diabetes;
pathological mechanism
- From:
International Eye Science
2024;24(7):1098-1101
- CountryChina
- Language:Chinese
-
Abstract:
Meibomian gland dysfunction is a chronic and diffuse disease of the meibomian glands, characterized by obstruction and(or)abnormal secretion of the terminal ducts. Clinically, it can lead to tear film abnormalities and inflammation of the ocular surface, resulting in symptoms of ocular irritation and potential corneal damage that may impact visual function. Meibomian gland dysfunction can be classified into two types based on meibomian gland secretion: low secretion type and high secretion type. The low secretion type further includes acinar atrophy type and obstruction type. In recent years, research has revealed that patients with diabetes experience chronic damage to their meibomian gland tissue in the early stages of the disease, leading to structural and functional changes. The incidence and severity of meibomian gland dysfunction are higher in diabetic patients. However, there are numerous complex factors contributing to this condition in diabetes patients, and mechanisms remain unclear at present. This article reviews both domestic and international research progress on the pathological mechanism underlying meibomian gland dysfunction in diabetes.
